Non-Gynecologic and Fine Needle Aspiration Cytopathology
Key Concepts
- Thyroid FNA: Bethesda System for Reporting Thyroid Cytopathology (I–VI); understand risk of malignancy and management.
- Salivary Gland FNA: Milan System categories; differentiate pleomorphic adenoma, Warthin tumor, mucoepidermoid carcinoma.
- Lymph Node FNA: Recognize reactive hyperplasia, granulomas, lymphoma, metastatic carcinoma.
- Body Fluid Cytology: Distinguish reactive mesothelial cells from adenocarcinoma; use ancillary tests (immunocytochemistry).
- Pancreaticobiliary and Lung FNA: Apply criteria for adenocarcinoma vs. reactive; molecular testing.
Common Traps
- Thyroid Bethesda III/IV: Atypia of undetermined significance (AUS) and follicular neoplasm have overlapping features; avoid overdiagnosis of malignancy.
- Salivary Gland Mimics: Mucoepidermoid carcinoma can mimic mucocele; look for intermediate cells and mucin.
- Mesothelial vs. Adenocarcinoma: Use panel (calretinin, CK5/6, WT1 vs. MOC-31, Ber-EP4, CEA).
- Lymphoma vs. Reactive: Monoclonality by flow cytometry is key; cytology alone may be insufficient.
- Lung FNA: Distinguish small cell from non-small cell; use immunocytochemistry (TTF-1, p40).
Rule of Thumb
For thyroid FNA with Bethesda IV (follicular neoplasm), diagnostic lobectomy is standard; repeat FNA is not recommended. For Bethesda III, repeat FNA or molecular testing.
Worked Example
Thyroid FNA shows microfollicles with scant colloid, Bethesda IV. Management: diagnostic lobectomy. If Bethesda III, consider Afirma or ThyroSeq to guide surgery.